Cognitive Disorders Treatment: How Neurologists Plan Care From Mild Impairment Onward

The appointment card sits on the kitchen counter for two weeks before anyone talks about it. A retired schoolteacher has started leaving the stove on, twice. Her son notices she tells the same story about the neighbor’s dog within ten minutes. She is sharp in every other way, still doing the crossword in pen, still winning at cards. So what exactly is a neurologist going to do?

That question is more useful than it sounds, because a cognitive disorders treatment plan is not a single prescription. It is a sequence of decisions, and the first several have nothing to do with tablets. The visit begins with a search for causes that can be fixed, moves through a careful description of what has changed, and only then turns to the question of medicines and monitoring.

Understanding that order helps families ask better questions and worry about the right things.

What does a cognitive disorders treatment plan actually include?

Start with the word itself. A cognitive disorder is any condition that impairs thinking skills such as memory, attention, language, judgment or the ability to plan, to a degree that is measurable and not explained by normal aging. Mild cognitive impairment (MCI) sits on the milder end: changes that are noticeable on testing but do not yet prevent someone from managing daily life. Dementia is the term used once those changes interfere with independence.

The plan a neurologist builds is layered rather than linear. At the base is the question of cause, because thyroid problems, low vitamin B12, depression, untreated sleep apnea and side effects of common medicines can all mimic or worsen cognitive decline. Above that sits management of the conditions that damage brain blood vessels, chiefly high blood pressure, diabetes and high cholesterol. The next layer covers lifestyle measures with real evidence behind them: regular physical activity, social engagement, hearing correction and good sleep. Medicines that act on brain chemistry come after that, and only for the specific diagnoses where they have been studied. Safety planning, caregiver support and legal preparation run alongside everything else.

The scale of the problem explains why this structured approach matters. The World Health Organization estimates that more than 55 million people live with dementia worldwide, with Alzheimer’s disease accounting for roughly 60–70% of cases, and nearly 10 million new cases each year. Behind each of those numbers is a family working out what to do first. A good plan answers that question in writing, revisits it on a schedule, and changes as the person changes. Nothing in it is fixed, and every element is a decision made with the treating team rather than a rule handed down.

How is cognitive impairment diagnosed before treatment begins?

No treatment plan is worth much without a clear diagnosis, and diagnosis in cognitive medicine is unusually dependent on listening. The neurologist wants to know what changed, when, how quickly, and who noticed. A spouse’s account often carries as much weight as the patient’s, because insight into one’s own memory can be one of the first things to fade.

The examination then moves through several steps. A brief cognitive screening test, a structured set of tasks such as recalling words, drawing a clock or naming animals, gives a first snapshot. Many people are referred on for neuropsychological testing, a longer session with a specialist psychologist that maps strengths and weaknesses across memory, language, attention and reasoning in far more detail. Blood tests look for the reversible contributors described later in this article. Brain imaging, usually magnetic resonance imaging (MRI), checks for strokes, tumors, fluid buildup or the pattern of shrinkage that points toward particular diseases.

Some centers add specialized tests when the result would change management. A lumbar puncture, which samples the fluid around the spinal cord, or a positron emission tomography (PET) scan, which uses a tracer to show protein deposits or brain activity, can indicate whether amyloid, a protein that clumps abnormally in Alzheimer’s disease, is present. According to the National Institute on Aging, these biomarker tests are increasingly used to clarify diagnosis in the earlier stages, though they are not needed for every person.

What emerges is not simply a label. The neurologist is describing a pattern: which domains are affected, how severely, and what the most likely cause is. That pattern determines whether the plan leans toward watchful monitoring, aggressive risk factor control, medication, or all three. Skipping this step and reaching straight for a prescription is the most common way plans go wrong.

What happens at the first neurology visits, step by step

Picture the first two or three appointments as one continuous process rather than separate events. The opening visit is mostly conversation and examination. The neurologist asks about medical history, family history, alcohol use, head injuries, mood, sleep and every medicine and supplement in the bathroom cabinet. A physical and neurological examination follows, checking reflexes, walking, eye movements and coordination, because certain patterns point toward specific diagnoses such as Parkinson’s-related conditions or small strokes.

Testing is usually ordered at that point, and results are reviewed at the second visit. This is where the plan starts to take shape. If bloodwork shows a correctable problem, that is addressed first and cognition is rechecked afterward. If imaging shows vascular damage, blood pressure and cholesterol targets move to the top of the list. If the pattern fits early Alzheimer’s disease, the discussion turns to what the evidence says about medicines for that stage, what monitoring would be involved, and what the person actually wants.

A written summary is a reasonable thing to expect. The NHS describes the post-diagnosis process as one that should include a named point of contact, information about the condition, and a review of ongoing care needs. In practice the summary might list the working diagnosis, the reversible factors being treated, the vascular targets, any medicine started with its purpose and review date, referrals to occupational therapy or speech therapy, and the date of the next cognitive reassessment.

Families sometimes leave the first visit disappointed that nothing was prescribed. That reaction is understandable but misplaced. Correcting a hearing deficit, stopping a sedating medicine or treating sleep apnea can produce more measurable change than any brain-specific drug, and those steps only happen when the early visits are done properly.

Who starts treatment now, and who is asked to watch and wait?

The phrase "watch and wait" alarms people, so it helps to be precise about what it means in cognitive care. It does not mean nothing is done. It means the brain-specific medicines are held back while everything else in the plan proceeds, and cognition is retested on a schedule to see which direction things are moving.

People with a confirmed dementia diagnosis, particularly Alzheimer’s disease, are the group most likely to be offered medication early, because that is where the trials were done. People with mild cognitive impairment are more often placed in structured monitoring. The reason is evidence rather than neglect: the Mayo Clinic notes that no medicine has been approved specifically for MCI and that cholinesterase inhibitors, a class of drugs discussed below, have not been shown to change the course of MCI reliably. The National Institute on Aging reports that estimates vary, but roughly 10–20% of people aged 65 or older with MCI develop dementia over a one-year period, which also means the majority do not within that window, and some return to normal cognition, especially when a reversible contributor is corrected.

Certain groups are more likely to be asked to wait for specific interventions. Anti-amyloid antibody treatments, a newer class given by infusion, are studied only in early-stage Alzheimer’s disease with confirmed amyloid, and the National Institute on Aging notes they require regular MRI scans to monitor for brain swelling or small bleeds. People with more advanced disease, without confirmed amyloid, with certain genetic profiles, on blood thinners or with other bleeding risks may be advised that the balance does not favor them. Those with severe depression, uncontrolled sleep disorders or active alcohol misuse are usually asked to address those first, because testing done under those conditions is not reliable.

Each of these calls belongs to the treating team, made with the person’s own priorities in the room.

Mild cognitive impairment treatment: what the evidence supports

Here is where the schoolteacher from the opening most likely lands, and where the evidence is both encouraging and modest. Mild cognitive impairment treatment rests on interventions that protect the brain broadly rather than on drugs aimed at a single disease.

Physical activity has the most consistent support. Regular aerobic exercise improves blood flow to the brain, helps control blood pressure and blood sugar, and is associated with slower decline in observational studies, according to the Mayo Clinic and the National Institute on Aging. The recommendation is not athletic: brisk walking most days of the week is the usual starting point, adjusted to what the person can safely do.

Cognitive and social engagement matter too. Learning a new skill, playing music, structured memory strategy training and simply staying socially connected are all associated with better outcomes, though the research cannot yet say precisely how much benefit any single activity delivers. The same honesty applies to diet: Mediterranean-style eating patterns are linked to lower dementia risk in population studies, but no specific food or supplement has been shown in rigorous trials to treat MCI. The NIH Office of Dietary Supplements has found no convincing evidence that vitamin E, ginkgo or omega-3 supplements improve cognition in people who are not deficient.

Hearing loss deserves special mention. The Cleveland Clinic and the NHS both list untreated hearing loss among the modifiable factors linked to cognitive decline, and hearing aids are a low-risk intervention with plausible mechanisms, including reduced cognitive load and better social participation.

Finally, MCI treatment includes scheduled retesting, typically at intervals the neurologist sets based on the pattern seen. The point is to catch change early, in either direction, and to have a plan ready for what to do next.

Medications for cognitive decline: what they do and what they cannot do

Medicines for cognitive disorders fall into a small number of classes, and understanding the mechanism of each makes the conversation with a prescriber far more productive. None of them is a recommendation here; all decisions sit with the treating clinician.

Cholinesterase inhibitors are the longest-established class. Acetylcholine is a chemical messenger involved in memory and attention, and its levels fall in Alzheimer’s disease. These drugs slow the enzyme that breaks acetylcholine down, leaving more available. The Mayo Clinic describes their effect as modest and temporary in some people, easing symptoms rather than altering the underlying disease. Side effects commonly involve the gut, sleep and heart rate. They are prescribed for Alzheimer’s dementia and some related conditions; as noted, evidence does not support them for MCI.

Memantine works differently, moderating the activity of glutamate, another messenger that can overstimulate and damage brain cells when present in excess. It is generally used in moderate to severe Alzheimer’s disease, sometimes alongside a cholinesterase inhibitor.

Anti-amyloid monoclonal antibodies are the newest class. They are laboratory-made proteins that bind to amyloid and help the immune system clear it. According to the National Institute on Aging, trials in early Alzheimer’s disease showed a slowing of decline over the study period, not an improvement, and treatment requires infusions plus regular MRI monitoring for amyloid-related imaging abnormalities, meaning swelling or small bleeds in the brain. Eligibility is narrow and screening is extensive.

Beyond these, a plan may include medicines for depression, anxiety, sleep or agitation when those symptoms are present, and equally may involve removing medicines. Drugs with anticholinergic effects, a property shared by some older antihistamines, bladder medicines and antidepressants, can worsen cognition, and a medication review is one of the most productive steps in the entire plan.

Which causes of cognitive impairment can be treated or reversed?

Every experienced neurologist has a story about the patient whose memory problem turned out to be a thyroid gland, a vitamin level or a sleep disorder. These cases are a minority, but they are exactly why the diagnostic workup is thorough before anyone talks about long-term medicines.

The list of reversible or partly reversible contributors is consistent across MedlinePlus, the Mayo Clinic and the NHS. Underactive thyroid slows thinking and can look very much like early dementia. Vitamin B12 deficiency, more common in older adults, vegetarians and people on certain acid-reducing or diabetes medicines, damages nerves and impairs memory. Depression in later life often presents with concentration and memory complaints rather than sadness, a pattern sometimes called pseudodementia; treating the mood disorder can restore cognition substantially. Obstructive sleep apnea, where breathing repeatedly stops during sleep, fragments rest and starves the brain of oxygen overnight, and its treatment can sharpen daytime thinking noticeably.

Medication side effects belong high on this list. Sedatives, sleeping tablets, strong painkillers and anticholinergic drugs can all cloud cognition, and the effect compounds when several are taken together. Alcohol, even at levels many people consider moderate, adds to the burden. Less common but important causes include normal pressure hydrocephalus, a buildup of fluid in the brain that produces a triad of walking difficulty, urinary urgency and cognitive slowing, and which can respond to a surgical shunt; subdural hematoma, a slow bleed under the skull after even a minor fall; and untreated infections or kidney and liver problems.

Delirium deserves its own sentence. It is an acute confusional state, often triggered by infection, dehydration or hospitalization, that develops over hours to days and fluctuates. It is a medical emergency, not a new diagnosis of dementia, and it is treated by finding and correcting the trigger. Recognizing the difference protects people from being labeled with a permanent condition they do not have.

How the plan changes from mild impairment onward: a summary table

Cognitive care is staged, and the emphasis shifts as the condition does. The table below summarizes how a typical neurologist-led plan evolves. It is a general map drawn from guidance published by the NHS, the Mayo Clinic and the National Institute on Aging, not a protocol; individual plans differ, and the treating team decides what applies.

Stage	Main goals	Usual components	Typical review focus
Subjective concern, normal testing	Rule out reversible causes; establish a baseline	Bloodwork, medication review, hearing and mood check, lifestyle counseling	Repeat testing if concern persists
Mild cognitive impairment	Slow progression; catch change early	Vascular risk control, exercise, cognitive and social engagement, sleep treatment, scheduled retesting	Direction of change on repeat tests; new symptoms
Mild dementia	Preserve independence and safety	All of the above plus disease-specific medicines where indicated, occupational therapy, driving and legal planning, caregiver education	Medicine tolerance and benefit; home safety; mood
Moderate dementia	Manage symptoms; support the caregiver	Medication adjustment, behavioral strategies for agitation or sleep disturbance, day programs, respite planning	Behavioral symptoms; caregiver strain; falls
Advanced dementia	Comfort, dignity, avoiding hospital when possible	Simplified medicines, palliative care involvement, swallowing and nutrition support, advance directive review	Comfort; infections; care setting

Two patterns stand out. First, the non-drug elements never drop off the list; they simply change form, from a walking program to a seated exercise class to gentle movement assisted by a carer. Second, the medicine list often gets shorter in the later stages rather than longer, because the goal shifts toward comfort and away from drugs whose benefit no longer outweighs their burden. That simplification is a clinical decision made deliberately, not a sign that care has been withdrawn.

Why blood pressure and heart health belong in a brain plan

Ask a neurologist what single measure most families underestimate, and blood pressure comes up repeatedly. The brain receives a large share of the heart’s output through a dense network of small vessels, and those vessels are damaged by the same forces that damage the coronary arteries: sustained high pressure, high blood sugar, high cholesterol and smoking.

The consequence is vascular cognitive impairment, which may occur on its own after strokes or, more commonly, alongside Alzheimer’s changes in a mixed picture. Imaging often shows small white spots or patches, evidence of damage to the brain’s wiring, in people who never had a recognized stroke. The Cleveland Clinic and the NHS both list high blood pressure, diabetes, high cholesterol, smoking and physical inactivity among the modifiable risk factors for cognitive decline and dementia.

This is why a cognitive disorders treatment plan reads, in part, like a cardiology plan. The American Heart Association’s Life’s Essential 8 framework, which covers diet, physical activity, nicotine exposure, sleep, weight, cholesterol, blood sugar and blood pressure, was designed for cardiovascular health, and the association notes that the same measures are linked to brain health. Managing these factors will not repair damage already done, and the evidence on how much it slows decline once impairment is established is less certain than the evidence for prevention. What the data do support is that uncontrolled vascular risk accelerates loss, and that controlling it is low-risk and beneficial for the heart regardless.

Practically, this means the neurologist and the primary care clinician need to communicate. Targets for blood pressure and blood sugar are set by the prescribing team with the individual’s overall health in mind, and overly aggressive lowering carries its own risks in older adults, including falls and dizziness. The plan works when those targets are agreed rather than assumed.

What the first weeks and months of a treatment plan look like

The pace of cognitive care surprises people who are used to the rhythm of, say, treating an infection. Change is measured in months, and the early period is more about building structure than watching for dramatic effects.

In the first few weeks after diagnosis, the practical items move fastest. Bloodwork results come back and any deficiency or thyroid problem is treated. A medication review happens, often with a pharmacist, and sedating or anticholinergic drugs are tapered or replaced under supervision. Referrals go out: to audiology if hearing is a factor, to a sleep clinic if apnea is suspected, to occupational therapy for a home assessment. If a disease-specific medicine is started, the early weeks are mainly about tolerance. Cholinesterase inhibitors, for instance, are commonly begun cautiously and adjusted by the prescriber, with the Mayo Clinic noting that side effects such as nausea, loss of appetite or sleep disturbance are the usual reason for changes in this period.

Over the following months, the plan settles into a monitoring rhythm. Cognitive retesting typically happens at intervals the neurologist sets, often somewhere between six months and a year according to Mayo Clinic guidance, sooner if something shifts. This is when the team judges whether a medicine appears to be helping, whether vascular targets are being met, and whether mood and sleep have improved. Families are usually asked to keep a simple log of noticeable changes, good or bad, because memory of gradual change is unreliable for everyone.

For those receiving anti-amyloid antibody infusions, the schedule is more intensive. The National Institute on Aging describes regular infusions plus periodic MRI scans during the first months to watch for swelling or bleeding, with the treating team reviewing each scan before continuing.

What families should expect from this phase is clarity rather than transformation: a clear sense of the diagnosis, the reasons behind each element of the plan, and who to call when questions arise.

How families, routines and the home become part of treatment

One of the quieter truths of cognitive medicine is that a well-organized home does more for daily function than most prescriptions. Neurologists know this, which is why the plan often includes an occupational therapist, a professional trained to adapt tasks and environments so that people can keep doing what matters to them.

Routine is the first tool. A consistent daily structure reduces the number of decisions a strained memory has to make, and predictable timing for meals, medicines, exercise and sleep anchors the day. Written schedules, a large calendar in a visible place, labeled cupboards and a single spot for keys and glasses all lower the cognitive load. The NHS suggests memory aids of exactly this kind as a core part of living well with memory problems.

Safety adjustments follow the pattern of loss. Automatic shut-off devices for stoves, removal of loose rugs, improved lighting and grab bars address the risks that matter most in the early stages: fire, falls and wandering. Medication management deserves specific attention, because taking tablets incorrectly is both a common cause of harm and a common trigger for a decline that looks like disease progression. Pill organizers, blister packs prepared by a pharmacy and supervision are practical steps; the treating team can advise which is suitable.

Family members become part of the treatment team whether they intended to or not, and the plan should account for that. Caregiver strain is a medical concern in its own right. The National Institute on Aging and the NHS both highlight caregiver education, support groups and respite arrangements as components of good dementia care rather than optional extras. A caregiver who is exhausted, isolated or unwell cannot sustain the routine that the person with the condition depends on.

Driving, finances and legal authority should be discussed early, while the person can participate fully. These conversations are hard, but they are far harder later.

What people often get wrong about a cognitive disorders treatment plan

Misconceptions cluster around cognitive care, partly because the subject is frightening and partly because the evidence is nuanced. Correcting the most common ones changes how families engage with the plan.

The first is that memory loss is simply normal aging and not worth investigating. Some slowing of recall is common with age, but forgetting recent events repeatedly, getting lost in familiar places or struggling with tasks that used to be routine is not, and the Mayo Clinic is explicit that these warrant evaluation. Delay costs the chance to correct a reversible cause and to plan while insight is intact.

The second is the opposite: that every diagnosis of MCI is early dementia. It is not. The National Institute on Aging notes that some people with MCI remain stable for years and some return to normal, particularly when a contributing factor is identified and treated. A diagnosis of MCI is a reason to act, not a sentence.

Third, people assume that if a medicine exists, it should be started, and that not starting one means the doctor has given up. The evidence for brain-specific medicines is stage-dependent and modest, and a decision not to prescribe at a given point is frequently the evidence-based choice. Conversely, some families believe supplements are a safe substitute; the NIH Office of Dietary Supplements has found no convincing evidence that popular products such as ginkgo or vitamin E improve cognition, and some interact with prescribed drugs.

Fourth, the sudden onset of confusion is often mistaken for a step down in the disease when it is actually delirium from an infection or dehydration, which is treatable and should be addressed urgently.

Finally, many assume the person with the diagnosis should be protected from the discussion. Most guidance, including from the NHS, favors involving them fully, because decisions about care, driving and finances are theirs to make for as long as they are able.

Questions to ask your care team

A neurology appointment moves quickly, and the most useful questions are the ones that clarify reasoning rather than seek reassurance. Writing them down beforehand, and bringing someone to take notes, is standard advice for good reason.

On diagnosis, ask what the working diagnosis is, how confident the team is, and what would change that confidence. Ask which cognitive domains are affected and which are preserved, because that shapes what daily support is actually needed. Ask whether any reversible contributors were found and how they are being addressed.

On the plan itself, ask what each element is meant to achieve. If a medicine is proposed, ask what it does, what benefit is realistic at this stage, what side effects are most likely, how tolerance will be checked, and when it will be reviewed. Ask whether any current medicines should be reduced or stopped, and who will coordinate that with the primary care clinician. If a medicine is not being offered, ask why, and what would make it appropriate later.

On monitoring, ask when cognition will be retested, what would prompt an earlier visit, and who the named contact is between appointments. Ask which specialists the person is being referred to and what each will do.

On daily life, ask about driving, work, managing money and living alone, and whether an occupational therapy home assessment is available. Ask what support exists for family carers and whether there is a local support group or education program.

On the future, ask what the likely course is, acknowledging that the honest answer is often a range. Ask when advance care planning should be discussed and what documents are worth preparing now. None of these questions is presumptuous. They are the questions a well-run clinic expects and welcomes.

When to call your doctor

Most changes in a cognitive condition unfold slowly and are handled at scheduled visits. Some do not, and knowing the difference can prevent serious harm.

Seek urgent care, calling emergency services where appropriate, for any sudden change: confusion that appears over hours or a day or two, especially with fever, a new cough, urinary symptoms or reduced fluid intake, which suggests delirium and an underlying infection or dehydration. A sudden inability to speak clearly, weakness or numbness on one side of the body, facial drooping, loss of vision or a severe abrupt headache are signs of stroke and need immediate emergency attention. A fall with a head strike, followed by drowsiness, vomiting, worsening headache or new confusion over the following days or weeks, requires prompt assessment for bleeding inside the skull. Seizures, fainting, or a marked change in walking or balance should be reported the same day.

Contact the care team promptly, though not necessarily as an emergency, when a newly started medicine brings nausea that prevents eating, dizziness, a very slow pulse, vivid nightmares or agitation; when mood drops sharply, sleep collapses, or the person expresses hopelessness or talks of not wanting to live; when hallucinations or marked suspiciousness appear; when weight is falling or swallowing becomes difficult; or when a carer is reaching the point of exhaustion. For anyone receiving anti-amyloid antibody infusions, the National Institute on Aging advises reporting new headache, confusion, dizziness, visual change or nausea without delay, because these can signal the brain swelling or bleeding that monitoring is designed to catch.

Between visits, the general rule is simple. Gradual change fits the expected course and belongs in the log for the next appointment. Sudden change, or anything that frightens you, warrants a call, and no reasonable clinician will think less of a family for making it.

Frequently asked questions

Can mild cognitive impairment be reversed?

Sometimes, yes. When mild cognitive impairment is driven by a treatable contributor such as thyroid disease, vitamin B12 deficiency, depression, sleep apnea or a sedating medicine, correcting that factor can restore cognition. The National Institute on Aging notes that some people with MCI return to normal and others remain stable for years. When the cause is an underlying neurodegenerative disease, the goal shifts to slowing decline and protecting function rather than reversal.

How is cognitive impairment diagnosed by a neurologist?

Diagnosis combines a detailed history from the person and someone who knows them well, a neurological examination, cognitive screening tests, blood tests for reversible causes, and usually brain imaging such as MRI. Many people also have neuropsychological testing, a longer session that maps specific strengths and weaknesses. In selected cases, spinal fluid analysis or PET scanning is used to look for the protein changes associated with Alzheimer’s disease.

What is the first step in a cognitive disorders treatment plan?

The first step is finding and correcting anything reversible. Before disease-specific medicines are discussed, the team checks thyroid function, vitamin levels, mood, sleep, hearing, alcohol use and every medicine and supplement being taken. Reducing sedating or anticholinergic drugs and treating sleep apnea or depression can produce measurable improvement. Establishing a clear baseline on cognitive testing at the same time allows later changes to be judged accurately.

What medications for cognitive decline are used, and how do they work?

Three main classes exist. Cholinesterase inhibitors slow the breakdown of acetylcholine, a memory-related messenger, and are used in Alzheimer’s dementia to ease symptoms. Memantine moderates glutamate, a messenger that can overstimulate brain cells, and is used in moderate to severe disease. Anti-amyloid monoclonal antibodies help clear amyloid protein in early Alzheimer’s disease and require infusion and MRI monitoring. Which, if any, is appropriate is a decision for the prescribing clinician.

How long does it take to know whether a treatment plan is working?

Longer than most people expect. Cognitive change is measured over months, and the Mayo Clinic describes repeat testing at intervals of roughly six months to a year to judge direction. Medicine tolerance is assessed in the first weeks, while any benefit is judged at the scheduled review. Reversible contributors such as a vitamin deficiency or sleep apnea may show clearer improvement once treated, which is why they are addressed first.

Is mild cognitive impairment treatment mostly lifestyle changes?

Largely, yes, because that is where the evidence sits. Regular aerobic activity, control of blood pressure, blood sugar and cholesterol, treating hearing loss and sleep disorders, staying socially and mentally engaged, and limiting alcohol form the core of MCI care according to the Mayo Clinic and the National Institute on Aging. No medicine is approved specifically for MCI, so scheduled retesting is included to catch change early.

Do supplements help with memory loss?

The evidence does not support them for people who are not deficient. The NIH Office of Dietary Supplements has found no convincing evidence that ginkgo, vitamin E, omega-3 products or similar supplements improve cognition or prevent dementia. Correcting a documented vitamin B12 deficiency is different and is part of standard care. Some supplements interact with prescribed medicines, so anything being taken should be disclosed to the treating team.

Why did the neurologist not prescribe anything at the first visit?

Because a diagnosis and a search for reversible causes come before brain-specific medicines, and because for mild cognitive impairment the evidence does not support the established drug classes. A plan built on medication review, vascular risk control, exercise, sleep and hearing care, with scheduled retesting, is an active treatment plan. If the picture later fits a diagnosis where medicines have evidence, that discussion follows at review.

What is the difference between delirium and dementia?

Delirium is an acute state of confusion that develops over hours to days, fluctuates, and is usually triggered by infection, dehydration, surgery or a medicine. Dementia develops gradually over months to years. People with dementia are more vulnerable to delirium, and an episode is often mistaken for disease progression. Delirium is a medical emergency treated by finding the trigger, and prompt care is essential.

Should the person with the diagnosis be involved in planning?

Yes, as fully as they are able, and for as long as possible. Guidance from the NHS and the National Institute on Aging favors open discussion of the diagnosis, the plan, driving, finances and future care preferences with the person at the center. Early involvement respects autonomy and makes later decisions easier for families, because wishes have been recorded while the person could express them clearly.

References

• World Health Organization: Dementia fact sheet
• National Institute on Aging (NIH): What Is Mild Cognitive Impairment?
• NHS: Dementia guide
• Cleveland Clinic: Mild Cognitive Impairment

This article is for general information only and is not a substitute for professional medical advice. Please consult a qualified doctor about your individual situation.